ALGS vs. ASMB, OPT, FENC, OTLK, VCXB, XFOR, CRDL, KOD, CLLS, and ADVM
Should you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Assembly Biosciences (ASMB), Opthea (OPT), Fennec Pharmaceuticals (FENC), Outlook Therapeutics (OTLK), 10X Capital Venture Acquisition Corp. III (VCXB), X4 Pharmaceuticals (XFOR), Cardiol Therapeutics (CRDL), Kodiak Sciences (KOD), Cellectis (CLLS), and Adverum Biotechnologies (ADVM). These companies are all part of the "medical" sector.
Assembly Biosciences (NASDAQ:ASMB) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.
Assembly Biosciences has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.
Assembly Biosciences has higher earnings, but lower revenue than Aligos Therapeutics.
Assembly Biosciences received 219 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 62.16% of users gave Aligos Therapeutics an outperform vote while only 59.31% of users gave Assembly Biosciences an outperform vote.
In the previous week, Assembly Biosciences had 9 more articles in the media than Aligos Therapeutics. MarketBeat recorded 12 mentions for Assembly Biosciences and 3 mentions for Aligos Therapeutics. Assembly Biosciences' average media sentiment score of 0.97 beat Aligos Therapeutics' score of 0.25 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
Assembly Biosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -783.72%. Aligos Therapeutics' return on equity of -120.58% beat Assembly Biosciences' return on equity.
19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 5.1% of Assembly Biosciences shares are owned by insiders. Comparatively, 16.5% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Assembly Biosciences beats Aligos Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Aligos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aligos Therapeutics Competitors List
Related Companies and Tools
